ECHOIQ LIMITED — Capital/Financing Update 2022

Jul 3, 2022

==> picture [595 x 112] intentionally omitted <==

ASX: EIQ RELEASE

4 JULY, 2022

ECHO IQ COMPLETES SALE OF PROMETHEUS INFORMATION PTY. LIMITED

Highlights

• Echo IQ successfully concludes sale of its Prometheus subsidiary to experienced software executives

• Echo IQ to focus fully on AI-backed cardiac innovation

Sydney, Australia: AI and Medical Technology company ECHOIQ Limited (“Echo IQ”, the Company) (ASX:EIQ) announces that it has completed the sale of wholly-owned subsidiary, Prometheus Information Pty. Limited (Prometheus) in line with the terms outlined in its announcement on 9 May, 2022.

As previously reported, Echo IQ is focussed on the use of artificial intelligence and data science to help improve detection of structural heart disease. The sale of Prometheus will allow the Company to maintain that focus on its strategic priorities whilst ensuring that current Prometheus clients have ongoing access to high levels of technical and commercial support.

Executive Chair Andrew Grover said: “With Echo IQ increasingly focussed on building and deploying its solutions in cardiac risk detection, the sale of Prometheus to highly experienced business leaders in the software and technology sector bodes well for existing clients.”

• ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair Andrew.grover@echoiq.ai / investors@echoiq.ai / +61 (0)481 339 512

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

==> picture [288 x 57] intentionally omitted <==